When choosing statin therapy: the case for generics

JAMA Intern Med. 2013 Feb 11;173(3):229-32. doi: 10.1001/jamainternmed.2013.1529.

Abstract

The development of "Top 5" lists across specialties and at regular intervals can help to remind physicians that optimal care is often possible at a lower cost. For purposes of cardiovascular risk reduction, generic statins, or their brand equivalents if priced similarly, remain the appropriate choice for dyslipidemic patients initiating statin therapy. In this article, we review the evidence supporting the choice of generic statins.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Choice Behavior
  • Drugs, Generic*
  • Dyslipidemias / complications
  • Evidence-Based Medicine
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Therapeutic Equivalency

Substances

  • Drugs, Generic
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors